On April 16, 2024, Clene Inc. announced the release of clinical trial results for its CNM-Au8 treatment in the VISIONARY-MS long-term extension trial for multiple sclerosis (MS). The results were presented at the 2024 American Academy of Neurology Annual Meeting and suggest that CNM-Au8 may aid in repair and remyelination in MS patients. The company shared this information through a presentation and a poster on its website, and also issued a press release. These materials were furnished as exhibits to the company's Current Report on Form 8-K filed with the SEC. Clene Inc. emphasized that the information provided, including the exhibits, is not to be considered filed for regulatory purposes nor incorporated by reference into any of their SEC filings.

On April 16, 2024, Clene Inc. announced the release of clinical trial results for its CNM-Au8 treatment in the VISIONARY-MS long-term extension trial for multiple sclerosis (MS). The results were presented at the 2024 American Academy of Neurology Annual Meeting and suggest that CNM-Au8 may aid in repair and remyelination in MS patients. The company shared this information through a presentation and a poster on its website, and also issued a press release. These materials were furnished as exhibits to the company's Current Report on Form 8-K filed with the SEC. Clene Inc. emphasized that the information provided, including the exhibits, is not to be considered filed for regulatory purposes nor incorporated by reference into any of their SEC filings.